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Matters arising
Chronic kidney disease and automatic reporting of estimated 
glomerular filtration rate
A recent position statement issued by the Australasian Creatinine Consensus Working Group sparked a 
lively response from our readers (Med J Aust 2005; 183: 138-141) 
Christop r  Florkowski,*
Wolf W Woltersdorf,* 
Peter M George,* Mohammed Saleem†
* Chemical Pathologist, †Chemical Pathology 
Registrar, Clinical Biochemistry Unit, Canterbury Health 
Laboratories, Hagley Avenue, Christchurch, 8002, 
New Zealand. chris.florkowski@cdhb.govt.nz
TO THE EDITOR: We were pleased to read
the position statement of the Australasian
Creatinine Consensus Working Group1 rec-
ommending that laboratories automatically
report estimated glomerular filtration rate
(eGFR) each time a serum creatinine test is
ordered in adults. We implemented this at
Christchurch Hospital in March 2005 after
consultation with key clinical staff. It has
been well received and has resulted in a
significant fall in the ordering of 24-hour
urine collections.
We firstly validated the performance of the
abbreviated MDRD (Modification of Diet in
Renal Disease) equation2 in a pilot study of
30 patients aged 40–85 years in a steady
state undergoing radionuclide GFR meas-
urement, adjusted for body surface area.
The MDRD calculation showed a mean bias
of –4.2 mL/min/1.73m2 (95% CI, –12.9 to
4.5 mL/min/1.73m2) compared with –
7.1 mL/min/1.73m2 (95% CI, –18.5 to
4.2 mL/min/1.73m2) for the Cockcroft–
Gault equation — thus, less bias and disper-
sion.
The position statement advocates measur-
ing serum creatinine concentration to the
nearest 1 mmol/L to avoid premature round-
ing of data in the calculation. However, other
studies have suggested that this is inappropri-
ately tight,3 and we contend that, although
this is an appropriate manipulation in the
calculation, it does not need to be preserved at
the point of reporting, when a creatinine
concentration to the nearest 10 mmol/L
would be sufficient.
At our hospital, “adult” status begins from
the age of 16 years, and clinicians expressed a
preference that we report eGFR from this
younger age. They also expressed a preference
that we report actual values rather than
“>60mL/min/1.73m2”. Given the absence of
well validated age-adjusted normative data,
we elected to give a reference range of 80–
120mL/min/1.73m2, while appending the
comment, “GFR declines by 1 mL/min/
1.73m2 per year over the age of 40 years”.
Also included in a comment with every report
is the caveat that eGFR is only valid under
steady-state conditions and that it has not
been validated for extremes of body mass or
in pregnant women, non-white populations,
oedematous patients or people with other
complex conditions.
If the creatinine concentration exceeds an
earlier value within the previous 4 days by
more than + 17% (a critical difference with
95% probability4), then an alternative com-
ment is issued indicating that steady-state
conditions are not met, although eGFR is still
reported. Similar considerations regarding
non-steady state apply equally to serum creat-
inine alone.
The position statement is helpful, but
should not be regarded as rigidly prescriptive.
Institutions should have the freedom to tailor
the package to their own requirements, based
on consultation with key clinicians.
1 The Australasian Creatinine Consensus Working
Group. Chronic kidney disease and automatic report-
ing of estimated glomerular filtration rate: a position
statement. Med J Aust 2005; 183: 138-141. 
2 Levey AS, Bosch JP, Lewis JB, et al. A more accurate
method to estimate glomerular filtration rate from
serum creatinine: a new prediction equation. Modifi-
cation of Diet in Renal Diseases Study Group. Ann
Intern Med 1999; 130: 461-470.
3 Badrick T, Wilson SR, Dimeski G, Hickman PE. Objec-
tive determination of appropriate reporting intervals.
Ann Clin Biochem 2004; 41: 385-390.
4 Fraser CG. Biological variation: from principles to
practice. Washington, DC: AACC Press, 2001. ❏
Michael P Metz
Clinical Pathologist, Core Laboratory, Women’s 
and Children’s Hospital, 72 King William Road, 
North Adelaide, SA 5006.
metzm@mail.wch.sa.gov.au
TO THE EDITOR: I applaud the recent
position statement of the Australasian Creati-
nine Consensus Working Group.1 It is in line
with worldwide support for the Kidney Dis-
ease Outcomes Quality Initiative (K/DOQI)
guidelines for chronic kidney disease2
expressed by the Renal Association of Great
Britain and the International Society of Neph-
rologists as well as North American groups.
However, I am concerned about universal
reporting of the Modification of Diet in Renal
Disease (MDRD) calculation of glomerular fil-
tration rate (GFR) applied to pregnant women.
As described in the K/DOQI guidelines,
the MDRD calculation has not been validated
in pregnancy. Other formulas are available
for calculating estimated GFR (eGFR) using
serum creatinine level and several other vari-
ables, yet none have been accepted for use in
pregnancy. A single study3 from 1994 fol-
lowed 34 women with impaired renal func-
tion through 38 pregnancies and compared
creatinine clearance derived from a 24-hour
urine collection with the Cockroft–Gault
eGFR during each trimester. While the study
showed good correlation between this eGFR
and creatinine clearance, I hesitate to recom-
mend national usage based on a single study
of 34 women. As recommended by the K/
DOQI guidelines and commonly used by
obstetricians, the accepted method for the
determination of GFR in pregnancy is still
the 24-hour urine collection with formal
calculation of creatinine clearance.
Pregnancy can occur in women with all
stages of renal impairment, including women
on dialysis or after transplantation. Fertility is
diminished and the risk of harm to the fetus is
increased if a woman with renal impairment
has a pre-pregnancy GFR of <70 mL/min/
1.73m2.4 Given that there is an almost 50%
increase in GFR between early pregnancy and
delivery,4 it is possible that even if the MDRD-
based eGFR accurately and precisely esti-
mated GFR, reporting high eGFR simply as
“>60mL/min” could result in failure to detect
renal impairment in some pregnant women.
While I strongly support the effort to
improve our recognition of chronic kidney
disease, I urge caution with regard to imple-
menting a scheme in the specific population
of pregnant women when this scheme has not
been adequately studied. Perhaps a multi-
centre cooperative study is in order.
1 The Australasian Creatinine Consensus Working
Group. Chronic kidney disease and automatic report-
ing of estimated glomerular filtration rate: a position
statement. Med J Aust 2005; 183: 138-141. 
2 National Kidney Foundation. K/DOQI clinical prac-
tice guidelines for chronic kidney disease: evaluation,
classification and stratification. Am J Kidney Dis 2002;
39 (2 Suppl 1): S1-S266.
3 Quadri K, Bernardini J, Greenberg A, et al. Assessment
of renal function during pregnancy using a random
urine protein to creatinine ratio and Cockcroft-Gault
formula. Am J Kidney Dis 1994; 24: 416-420.
4 Davidson J, Bayliss C. Renal disease. In: de Swiet M,
editor. Medical disorders in obstetric practice. 4th ed.
Oxford: Blackwell Science Ltd, 2002. ❏MJA • Volume 184 Number 1 • 2 January 2006 41
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TO THE EDITOR: The Australasian Creati-
nine Consensus Working Group has issued
an important statement1 that highlights the
perils of relying on serum creatinine concen-
tration alone to estimate kidney function.
However, the suggestion that the recom-
mended eGFR (estimated glomerular filtra-
tion rate) “is not appropriate for use . . . [in
certain groups, such as] Aboriginal and
Torres Strait Islander populations” and that
“GFR should be measured directly” in such
populations is poorly worded and clinically
inappropriate.
The two most commonly used formulas for
eGFR calculation (the Cockroft–Gault and
MDRD [Modification of Diet in Renal Disease]
equations) are both derived from studies in
US subjects, with a correction factor added for
African-Americans.2,3 Concerns have recently
been raised about other ethnic groups.4 As
neither formula has been validated in any
specific Australian majority or minority
group, to recommend exclusion of Aboriginal
and Torres Strait Islander populations without
data is inappropriate.
In the Northern Territory, rates of kidney
disease in Indigenous Australians are 20–30
times those in the white population. In addi-
tion, Indigenous Australians have limited
access to basic health care, let alone “direct
measurements of GFR”. We believe that, until
data are available on the validity of the MDRD
formula for specific minority groups, the best
clinical care can be delivered by measuring
the serum creatinine concentration and calcu-
lating eGFR (using the MDRD equation) in all
Australians. We have been using this
approach for over 2 years.
Therefore we suggest the following altern-
ative to the Working Group’s recommendation:
Estimated GFR should be reported for all
people aged 18 years, but cautious
interpretation should be used in popula-
tion groups with limited or no validation
data.
1 Australasian Creatinine Consensus Working Group.
Chronic kidney disease and automatic reporting of
estimated glomerular filtration rate: a position state-
ment. Med J Aust 2005; 183: 138-141. 
2 Cockroft D, Gault MK. Prediction of creatinine clear-
ance from serum creatinine. Nephron 1976; 16: 31-41.
3 Levey AS, Bosch JP, Lewis JB, et al. A more accurate
method to estimate glomerular filtration rate from
serum creatinine: a new prediction equation. Modifi-
cation of Diet in Renal Disease Study Group. Ann
Intern Med 1999; 130: 461-470.
4 Zuo L, Ma Y-C, Zhou Y-H, et al. Application of GFR-
estimating equations in Chinese patients with chronic
kidney disease. Am J Kidney Dis 2005; 45: 463-472. ❏
Terry E Jones
Clinical Pharmacist, Pharmacy Department, 
The Queen Elizabeth Hospital, Woodville Road, 
Woodville South, SA 5011. 
terry.jones@nwahs.sa.gov.au.
TO THE EDITOR: I read with interest the
position statement1 recommending that
Australian laboratories use the recently pub-
lished MDRD (Modification of Diet in Renal
Disease) equation2 to estimate glomerular
filtration rate (GFR) and automatically
report the estimated GFR (eGFR) when the
value is less than 60 mL/min/1.73m2.
Serum creatinine concentration provides an
imperfect guide to renal function because it is
affected by factors other than glomerular fil-
tration. To improve the accuracy of the esti-
mate of GFR, more than 40 equations and
nomograms have been developed over the
years. One of these, the MDRD equation, was
found to give a better estimate than the most
commonly used equation (the Cockcroft–
Gault equation3)  in a study that (it might be
argued) favoured the MDRD method.2 The
abbreviated MDRD equation recommended
in the position statement has only been pub-
lished as an abstract.4
The position statement notes that “an
uncorrected eGFR may be preferred for clin-
ical use in some situations, such as drug
dosing”, which requires the reported eGFR to
be modified for body surface area (BSA).
However, the formula quoted in the position
statement is incorrect. The correct formula,
published in 19165 is:
BSA = W0.425   H0.725   0.007184
This complicated equation requires data
that are infrequently available, and it is argu-
able that performing this extra calculation
may negate any benefit from the “improved”
MDRD estimate. While the authors of the
position statement do not recommend that
reported eGFRs be used to calculate drug
doses for patients with renal impairment, it is
likely that they will be used for that purpose,
without modification, by prescribers unaware
of the limitations.
For patients requiring drug dosage reduc-
tions, it is doubtful whether the MDRD for-
mulas give a more accurate eGFR than the
Cockcroft–Gault equation, which has not
only provided useful bedside estimates of
GFR for decades, but has also been a valuable
teaching tool. By incorporating age, sex and
weight, the Cockcroft–Gault equation
reminds us that these factors affect creatinine
production and hence serum creatinine con-
centration. The same cannot be said for the
MDRD formulas, which are complex, difficult
to remember, and require a personal digital
assistant or similar device for doing the calcu-
lations.
In estimating the dose of renally cleared
drugs, it has been observed that “what is
essential for therapeutic decisions is knowing
that a patient’s renal function is impaired and
about to what extent, rather than the exact
glomerular filtration rate”.6 Since estimates of
renal function will never preclude drug con-
centration monitoring, modest improvements
in accuracy of an estimated parameter are of
limited benefit. I recommend the continued
use of the Cockcroft–Gault equation for esti-
mating doses of renally cleared drugs.
1 Australasian Creatinine Consensus Working Group.
Chronic kidney disease and automatic reporting of
estimated glomerular filtration rate: a position state-
ment. Med J Aust 2005; 183: 138-141. 
2 Levey AS, Bosch JP, Lewis JB, et al. A more accurate
method to estimate glomerular filtration rate from
serum creatinine: a new prediction equation. Modifi-
cation of Diet in Renal Disease Study Group. Ann
Intern Med 1999; 130: 461-470.
3 Cockcroft DW, Gault MH. Prediction of creatinine
clearance from serum creatinine. Nephron 1976; 16:
31-41.
4 Levey AS, Greene T, Kusek JW, et al. A simplified
equation to predict glomerular filtration rate from
serum creatinine [abstract]. J Am Soc Nephrol 2000;
11: A828.
5 DuBois D, DuBois EF. A formula to estimate the
approximate surface area if height and weight be
known. Arch Intern Med 1916; 863-871.
6 Reidenberg MM. Kidney function and drug action.
N Engl J Med 1985; 13: 816-817. ❏
Richard X Davey
Chemical Pathologist, Melbourne Health Shared 
Pathology Service, Royal Melbourne Hospital, 
Parkville, VIC 3050.
richard.davey@wh.org.au
TO THE EDITOR: The publication of an
Australasian position statement on reporting
estimated glomerular filtration rates (eGFRs)1
is welcome. It may, however, contain errors
and unexplained assumptions.
Firstly, along with its US2 and UK3 counter-
parts, the position statement recommends the
use of the MDRD (Modification of Diet in
Renal Disease) four-variable formula to derive
eGFR from a patient’s serum creatinine level.
Results obtained using this formula are more
accurate than those from a patient’s calculated
creatinine clearance rate. In accordance with
the US guidelines, the Australasian position
statement specifies that the total error in labor-
atories’ serum creatinine measurements should
be less than ±15% if they are to meet overall
reporting acceptability. It claims that results
that lie within ±15% of results derived from
the reference method procedure (isotope dilu-
tion mass spectrometry) also lie within ±15%
of results based on applying the MDRD for-
mula to CX3 analyser readings and thus “fulfil42 MJA • Volume 184 Number 1 • 2 January 2006
MATTERS ARISINGthe accuracy criterion”. Australian physicians
should be wary of this claim. Assays from
which the MDRD formula was derived were
reportedly performed on an older analyser
than the CX3,4 with possibly even less accurate
results. Serum creatinine results produced by a
CX3 analyser are themselves about 16% posi-
tively biased compared with results calculated
by the reference method.5 It is thus possible to
be within 15% of a CX3 result and yet, at
worst, be >30% shy of the “true” creatinine
value assayed by the reference method. Labo-
ratories should explain to clinician clients the
limitations of their creatinine assays.
Secondly, the precision of an assay varies
with the level of analyte being analysed — a
nuance to be considered, but too technically
complex to address further here. The position
statement barely touches on this issue.
Thirdly, the position statement opts for
60mL/min/1.73m2 as the upper limit for reli-
able reporting of eGFR. It offers reasons why it
takes this approach, but does not explain why
the chosen level varies from US and UK
reporting practices (both choose 90mL/min/
1.73m2 as the cut-off point).
Finally, the UK guidelines sensibly changed
the US terminology for racial derivation from
“African-American” to “African-Caribbean”
when indicating a need to adjust the eGFR
reported. The Australasian position statement
adopts the term “African-American”. Austral-
ian Africans are not African-Americans, nor
do all Africans have similar physical stature to
people whose ancestors lived in sub-Saharan
west and central Africa and who became
slaves in the United States or lived in English
Caribbean colonies. More care will be needed
in reporting here if clinicians are not to be
needlessly confused.
1 Australasian Creatinine Consensus Working Group.
Chronic kidney disease and automatic reporting of
estimated glomerular filtration rate: a position state-
ment. Med J Aust 2005; 183: 138-141. 
2 National Kidney Foundation. K/DOQI clinical practice
guidelines for chronic kidney disease: evaluation,
classification and stratification. Am J Kidney Dis 2002;
39 (2 Suppl 1): S1-S266. Available at: http://www.kid-
ney.org/professionals/kdoqi/guidelines_ckd/toc.htm
(accessed Jul 2005).
3 Joint Specialty Committee on Renal Disease. Chronic
kidney disease in adults: UK guidelines for identifica-
tion, management and referral. June 2005. Available
at: http://www.renal.org/CKDguide/full/UKCKD-
full.pdf (accessed Jul 2005).
4 Levey AS, Bosch JP, Lewis JB, et al. A more accurate
method to estimate glomerular filtration rate from
serum creatinine: a new prediction equation. Modi-
fication of Diet in Renal Disease Study Group. Ann
Intern Med 1999; 130: 461-470.
5 Miller WG, Myers GL, Ashwood ER, et al. Creatinine
measurement: state of the art in accuracy and inter-
laboratory harmonization. Arch Pathol Lab Med 2005;
129: 297-304. ❏
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IN REPLY: Jose and Lawton identify a concern
about the wording in the position statement
relating to one of the caveats on the use of
estimated glomerular filtration rate (eGFR).
The intention of the Australasian Creatinine
Consensus Working Group was to highlight
that, in certain populations, the MDRD (Modi-
fication of Diet in Renal Disease) formula for
calculating GFR has not been validated, and
that, in such populations, caution should be
exercised in applying the formula. This con-
servative approach was deemed appropriate, as
significant population differences in muscle
mass (such as have been documented between
whites and African-Americans and between
men and women) could lead to a formula
correction factor being applied in these groups.
It was not the intention of the Working
Group to deny the advantages of automatic
reporting of eGFR to any section of the com-
munity. The sparse evidence that exists sug-
gests that the amount of fat-free mass found in
Indigenous Australians does not differ from
that found in non-Indigenous Australians.1 In
retrospect, it may have been more appropriate
for the position statement not to have singled
out Indigenous Australians for special mention.
The real need is for the eGFR formula to be
validated in Aboriginal and Torres Strait
Islander populations so that a firm basis for its
use can be established and a correction factor
applied if that is found to be required. Until
this evidence is available, it appears clinically
appropriate for the eGFR to be calculated and
used prudently in Indigenous Australians.
Jones is mistaken in stating the body surface
area formula we quoted is incorrect. The for-
mula is expressed with the correction factor to
normal body size incorporated, and is correct
in the context in which it was used. We agree
with his recommendation to continue using
the Cockcroft–Gault formula for estimating
doses of drugs cleared by the kidney, at least
until evidence for this purpose is accumulated
using the MDRD formula.
Davey raises the possibility that significant
errors may occur as a result of poor standard-
isation of serum creatinine assays. There is
indeed room for improvement in routine
assays for serum creatinine, but we believe,
based on available data, that the current assays
from most major suppliers are suitable for the
purpose. Further details on acceptable assays
have been provided by the Working Group for
all Australian laboratories.2 Davey notes the
presence of two reference standards for serum
creatinine in the position statement: the CX3
method (which was used in the original
MDRD article) and the international reference
method (IRM). We believe that assays aligned
with either of these standards meet the specifi-
cations, as the IRM gives lower results than the
CX3 method and there are no current com-
mercial assays giving results lower than the
IRM. Thus, any current assays within 15% of
the IRM are higher than the IRM and within
15% of the CX3 method. Furthermore, the
claim of a positive bias of 16% for the current
CX3 assay is taken at a single creatinine con-
centration that is below those that may be used
for eGFR calculations. As this bias is absolute
rather than proportional, it is not as marked at
higher creatinine concentrations. Other studies
do not support this degree of difference.
We agree that improvements in creatinine
assay standardisation will be of benefit, and
this issue is actively being pursued by working
groups of the International Federation of Clin-
ical Chemistry and Laboratory Medicine and
the National Kidney Disease Education Pro-
gram (NKDEP). Indeed, the attention given to
serum creatinine assays as part of the delibera-
tions of these groups is of benefit to any clinical
assessment based on serum creatinine results.
The upper limit of reporting eGFR, recom-
mended at 60 mL/min/1.73m2, is in keeping
with the position statement of the NKDEP in
the United States,3 although not with the
position of the Renal Association in the
United Kingdom, which recommends report-
ing up to 90 mL/min/1.73m2.4 At this stage,
we believe that assay variability at lower
creatinine concentrations and lack of valida-
tion of the MDRD formula at higher values for
eGFR make 60 mL/min/1.73m2 a suitable
starting point. We hope that, with improve-
ments in both these factors, a higher limit
may be acceptable.
1 Rutishauser IH. Body composition in Aboriginal Aus-
tralians. Asia Pacific J Clin Nutr 1995; 4: 73-76.
2 Jones G, for the Working Party on routine reporting
of eGFR. Routine reporting of eGFR. Laboratory
implementation guidelines. Available at: http://
www.aacb.asn.au/pubs/eGFR%20Laboratory
%20Guidelines.PDF (accessed Nov 2005).
3 National Kidney Disease Education Program.
Resources: suggestions for laboratories. Available at:
http://www.nkdep.nih.gov/resources/laboratory_
reporting.htm (accessed Nov 2005).
4 Joint Specialty Committee on Renal Disease. Chronic
kidney disease in adults: UK guidelines for identifica-
tion, management and referral. June 2005. Available
at: http://www.renal.org/CKDguide/full/UKCKD-
full.pdf (accessed Jun 2005). ❏MJA • Volume 184 Number 1 • 2 January 2006 43
